Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Joanne M. Mankor"'
Autor:
Sophie M. Ernst, Joanne M. Mankor, Job van Riet, Jan H. von der Thüsen, Hendrikus J. Dubbink, Joachim G.J.V. Aerts, Adrianus J. de Langen, Egbert F. Smit, Anne-Marie C. Dingemans, Kim Monkhorst
Publikováno v:
Journal of Thoracic Oncology, 18(4), 487-498. International Association for the Study of Lung Cancer
Introduction: Patient-reported smoking history is frequently used as a stratification factor in NSCLC-directed clinical research. Nevertheless, this classification does not fully reflect the mutational processes in a tumor. Next-generation sequencing
Autor:
Joanne M. Mankor, Maria J. Disselhorst, Myrthe Poncin, Paul Baas, Joachim G.J.V. Aerts, Heleen Vroman
Publikováno v:
EBioMedicine, Vol 62, Iss , Pp 103040- (2020)
Background: Combined immune checkpoint inhibitor (ICI) treatment targeting PD-1 and CTLA-4 was suggested to yield clinical benefit over chemotherapy in malignant pleural mesothelioma (MPM), whereas aPD-1 monotherapy failed to provide benefit in phase
Externí odkaz:
https://doaj.org/article/ff10acfc49ea49d688bba34a12ea726f
Autor:
Daphne W. Dumoulin, Luca Cantini, Robin Cornelissen, Madelief Vink, Larissa Klaase, Kick Slooff, Nura Tebayna, Joanne M. Mankor, Sara J. Baart, Rudi Hendriks, Anne-Marie C. Dingemans, Marcella Willemsen, Joachim G.J.V. Aerts
Publikováno v:
European Journal of Cancer, 172, 357-366. Elsevier Ltd.
Purpose: Lurbinectedin is a promising new drug being investigated in pre-treated patients with small cell lung cancer (SCLC) or malignant pleural mesothelioma (MPM). Its clinical activity in the real-world setting has not been investigated yet. Patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d806d365d895d4fde983300eefbfe7b1
https://pure.eur.nl/en/publications/c7ab20d9-63c7-41f2-95e2-02a4cf6bc3f1
https://pure.eur.nl/en/publications/c7ab20d9-63c7-41f2-95e2-02a4cf6bc3f1